CSI Market
Sign In | Register

Pure Bioscience Inc (PURE) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PURE Annual Cash Flow →
This cash flow overview for Pure Bioscience Inc spans from Apr 30 2025 to Apr 30 2026, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Apr 30 2026)
9 Months 		(Jan 31 2026) (Oct 31 2025) (Jul 31 2025) (Apr 30 2025)
Operating Activities
Income-1.87
Depreciation & amortization0.00
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Long-Lived Assets to be Disposed of0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.09
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation0.15
Income (Loss) from Equity Method Investments0.00
Increase (Decrease) in Restricted Cash for Operating Activities0.00
Amortization Stock Issued Under Purchase Agreement-
Amortization Stock Issued Under Bridge Loan-
Stock Issued-
Stock Issued Under Purchase Agreement-
Amortization Of Stock Issued For Services-
Stock Issued For Severance-
Stock Issued To Investors To Amend Subscription Agreements-
Warrant Penalty-
Extinguishment Of Debt Gain Loss Net Of Tax-
Stock Issued For Services-
Inducement To Exercise Warrants-
Computer Software Impairments-
Income taxes0.00
Unrealized Gain (Loss) on Derivatives and Commodity Contracts0.00
Increase (Decrease) in Accounts Receivable0.23
Increase (Decrease) in Accounts Payable and Accrued Liabilities-0.04
Increase (Decrease) in Interest Payable, Net0.29
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.01
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-1.32
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.97
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.47
Proceeds From Exercise Of Stock Options And Warrants-
Net Proceeds From Bridge Loan Financing-
Increase Decrease In Deferred Financing Costs-
Net Proceeds From Exercise Of Warrants-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents1.06
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations0.41
Net Proceeds From Payroll Protection Program Loan-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.97
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-1.32
Total Cash Flow0.65
4 historic quarters locked

Sign in to unlock the full Pure Bioscience Inc cash flow history.

Sign In Create Free Account

About Pure Bioscience Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260430)
  • Filed with the SEC: June 15, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-028691

Figures are derived from filed reports and may be restated. Historical data is subject to revision.